Lim Ming Tsuey, Ab Rahman Norazida, Teh Xin Rou, Chan Chee Lee, Thevendran Shantini, Ahmad Hamdi Najwa, Lim Ka Keat, Sivasampu Sheamini
Institute for Clinical Research, National Institutes of Health, Ministry of Health, Malaysia.
Institute for Clinical Research, National Institutes of Health (NIH), Ministry of Health Malaysia, Block B4, No. 1, Jalan Setia Murni U13/52, Shah Alam, Selangor, 40170, Malaysia.
Ther Adv Chronic Dis. 2021 Feb 17;12:2040622321990264. doi: 10.1177/2040622321990264. eCollection 2021.
Medication adherence measures are often dichotomized to classify patients into those with good or poor adherence using a cut-off value ⩾80%, but this cut-off may not be universal across diseases or medication classes. This study aimed to examine the cut-off value that optimally distinguish good and poor adherence by using the medication possession ratio (MPR) and proportion of days covered (PDC) as adherence measures and glycated hemoglobin (HbA1c) as outcome measure among type 2 diabetes mellitus (T2DM) patients.
We used pharmacy dispensing data of 1461 eligible T2DM patients from public primary care clinics in Malaysia treated with oral antidiabetic drugs between January 2018 and May 2019. Adherence rates were calculated during the period preceding the HbA1c measurement. Adherence cut-off values for the following conditions were compared: adherence measure (MPR PDC), assessment period (90-day 180-day), and HbA1c target (⩽7.0% ⩽8.0%).
The optimal adherence cut-offs for MPR and PDC in predicting HbA1c ⩽7.0% ranged between 86.1% and 98.3% across the two assessment periods. In predicting HbA1c ⩽8.0%, the optimal adherence cut-offs ranged from 86.1% to 92.8%. The cut-off value was notably higher with PDC as the adherence measure, shorter assessment period, and a stricter HbA1c target (⩽7.0%) as outcome.
We found that optimal adherence cut-off appeared to be slightly higher than the conventional value of 80%. The adherence thresholds may vary depending on the length of assessment period and outcome definition but a reasonably wise cut-off to distinguish good poor medication adherence to be clinically meaningful should be at 90%.
药物依从性测量通常被二分法化,使用≥80%的临界值将患者分为依从性好或差的两类,但该临界值可能并非在所有疾病或药物类别中通用。本研究旨在通过使用药物持有率(MPR)和覆盖天数比例(PDC)作为依从性测量指标,糖化血红蛋白(HbA1c)作为2型糖尿病(T2DM)患者的结局指标,来检验能最佳区分依从性好与差的临界值。
我们使用了2018年1月至2019年5月期间在马来西亚公立基层医疗诊所接受口服抗糖尿病药物治疗的1461例符合条件的T2DM患者的药房配药数据。在糖化血红蛋白测量前的时间段内计算依从率。比较了以下条件下的依从性临界值:依从性测量指标(MPR、PDC)、评估期(90天、180天)以及糖化血红蛋白目标(≤7.0%、≤8.0%)。
在两个评估期内,MPR和PDC预测糖化血红蛋白≤7.0%的最佳依从性临界值在86.1%至98.3%之间。在预测糖化血红蛋白≤8.0%时,最佳依从性临界值在86.1%至92.8%之间。以PDC作为依从性测量指标、评估期较短以及以更严格的糖化血红蛋白目标(≤7.0%)作为结局时,临界值明显更高。
我们发现最佳依从性临界值似乎略高于传统的80%。依从性阈值可能因评估期长度和结局定义而异,但要在临床上具有意义,区分药物依从性好与差的合理明智的临界值应为90%。